Published Date: 28-Feb-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global RNA Based Therapeutic Market, published by KBV research, The Global RNA Based Therapeutic Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 15.1% CAGR during the forecast period.
The RNA Interference (RNAi) market will exhibit the growth rate of 15.7% during (2021 - 2027). Interfering RNA is a type of short, non-coding RNA that suppresses gene expression during or after translation. Short interfering RNA (siRNA) and micro RNA (miRNA) have been identified as major effectors of post-transcriptional gene regulation, making them promising treatments for systemic illnesses. Jorgensen et al. discovered the RNAi system in 1990 while working on a project including the introduction of color genes into petunias. This system is hypothesized to have evolved as a means of innate defense over double-stranded RNA viruses.
The Genetic disorders market is leading the Global RNA Based Therapeutic Market by Application 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $8.7 billion by 2027. The increasing growth of this segment of the market is attributed to the rising number of cases of genetic diseases and molecular diagnostics along with rare disorders. The number of patients that are adopting this method for the treatment is constantly increasing and owing to the upsurge of the growth for genetic disorders segment of the market.
The Hospitals & Clinics market shows high growth rate of 17% during (2021 - 2027). The rising growth of this segment of the market is attributed to the increased number of developments across the healthcare infrastructure throughout the world including the adoption of modern and advanced technologies.
The North America segment dominated the Global RNA Based Therapeutic Market by Region 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $5.4 billion by 2027. The Europe market is estimated to witness a CAGR of 14.9% during (2021 - 2027). Additionally, The Asia Pacific market would experience a CAGR of 15.6% during (2021 - 2027).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.
By End User
Unique Offerings from KBV Research